Alpha 2.0
Login Register
» Authors » Ann Olmsted

Ann Olmsted

Explore the profile of Ann Olmsted including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 317
Followers 0
Related Specialty
Cardiology & Vascular Diseases
Top 10 Co-Authors
Luiz Belardinelli
Ori Ben-Yehuda
Brent Blackburn
Darren K McGuire
Philip G Jones
John A Spertus
Mikhail Kosiborod
Whedy Wang
Patrick Yue
Suzanne V Arnold
Published In
J Nucl Cardiol
J Am Coll Cardiol
Am Heart J
Circ Arrhythm Electrophysiol
Affiliations
Soon will be listed here.
Recent Articles
1.
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism
Reiffel J, Camm A, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, et al.
Circ Arrhythm Electrophysiol . 2015 Aug; 8(5):1048-56. PMID: 26226999
Background: Atrial fibrillation (AF) requires arrhythmogenic changes in atrial ion channels/receptors and usually altered atrial structure. AF is commonly treated with antiarrhythmic drugs; the most effective block many ion channels/receptors....
2.
Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c
Arnold S, McGuire D, Spertus J, Li Y, Yue P, Ben-Yehuda O, et al.
Am Heart J . 2014 Sep; 168(4):457-465.e2. PMID: 25262254
Background: Ranolazine reduces the frequency of angina and use of sublingual nitroglycerin (SL NTG) in stable angina patients with type 2 diabetes (T2DM). Because pre-clinical data suggest that myocardial late...
3.
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial
Weisz G, Farzaneh-Far R, Ben-Yehuda O, deBruyne B, Montalescot G, Lerman A, et al.
Am Heart J . 2013 Nov; 166(6):953-959.e3. PMID: 24268208
Background: Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the...
4.
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)
Kosiborod M, Arnold S, Spertus J, McGuire D, Li Y, Yue P, et al.
J Am Coll Cardiol . 2013 Mar; 61(20):2038-45. PMID: 23500237
Objectives: This study sought to examine the efficacy of ranolazine versus placebo on weekly angina frequency and sublingual nitroglycerin use in subjects with type 2 diabetes mellitus, coronary artery disease...
5.
Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging
Reyes E, Staehr P, Olmsted A, Zeng D, Blackburn B, Cerqueira M, et al.
J Nucl Cardiol . 2011 May; 18(4):620-7. PMID: 21553161
Background: There are limited data on the effect of body mass index (BMI) on the actions of fixed-dose regadenoson. The purpose of this study was to determine the effect of...
6.
Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial
Gaemperli O, Schepis T, Koepfli P, Siegrist P, Fleischman S, Nguyen P, et al.
J Am Coll Cardiol . 2008 Jan; 51(3):328-9. PMID: 18206744
No abstract available.
7.
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial
Iskandrian A, Bateman T, Belardinelli L, Blackburn B, Cerqueira M, Hendel R, et al.
J Nucl Cardiol . 2007 Sep; 14(5):645-58. PMID: 17826318
Background: Earlier phase 1 and 2 studies have shown that regadenoson has desirable features as a stress agent for myocardial perfusion imaging. Methods And Results: This multicenter, double-blinded phase 3...